Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 IT or OAV101 IV in Clinical Trials

NCT05335876 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT05335876
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05335876 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 IT or OAV101 IV in Clinical Trials
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 19, 2022
Completion date
April 30, 2031
Enrollment
20 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

spinal muscular atrophy (sma)